Cogent Biosciences, Inc. — Director's Dealing 2019

Jun 25, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Unum Therapeutics Inc. (UMRX)
CIK: 0001622229
Period of Report: 2019-06-24

Reporting Person: Osborne Matthew Scott (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-24	Stock Option (Right to Buy)	$2.44	A	190000	Acquired	2029-06-24	Common Stock (190000)	Direct

Footnotes

F1: This stock option shall vest as follows: 25% on the first anniversary of the date of grant then in equal monthly installments over 36 months.